Dopamine D2 receptor agonists are commonly used in the control of PRL-secreting adenomas, and the sensitivity of dopamine agonists during long term therapy is exquisite. However, the molecular mechanisms responsible for the maintenance of this cellular sensitivity to dopamine agonists remain poorly understood. In the present study, we examined the agonist-induced regulation of the human D2 L receptor expressed to a specific activity of ϳ1 pmol receptor/mg protein in Sf9 insect cells. Treatment of D2 L receptor-expressing cells with dopamine for up to 3 h resulted in no detectable change in the ligandbinding properties of the receptor and a ϳ120-fold reduction in the potency, but not the efficacy, of D2 L receptors to mediate dopamine inhibition of forskolin-stimulated adenylyl cyclase activity. This resistance of the D2 L receptor to agonist-induced desensitization was accompanied by a ϳ28% translocation of intracellular D2 L receptors to the cell surface, as quantified by cellular fractionation and radioligand binding and visualized by whole cell immunocytochemical staining and confocal microscopy. Immunoblot analysis of the P2 membrane fraction revealed that surface D2 L receptors comprised monomers and dimers. Treatment of D2 L receptor-expressing cells with the protein synthesis inhibitor cycloheximide significantly reduced the basal expression level of receptors, but did not block the agonist-induced up-regulation of receptors. Longer periods of dopamine exposure for 24 h brought about a small increase in surface receptor density. However, when these studies were conducted in the presence of cycloheximide, receptor density was marginally reduced, suggesting that receptor synthesis accounts for the maintenance of cellular receptor density under these conditions. We conclude that the resistance of the D2 L receptor-coupled adenylyl cyclase system to agonist-induced desensitization is attributed to the up-regulation of surface receptors after the translocation of existing intracellular receptors and de novo receptor synthesis. (Endocrinology 138: 4199 -4206, 1997) D OPAMINE receptors have been categorized on the basis of differences in pharmacological and biochemical characteristics and structure into the D1-like receptors, which include D1 and D5 receptors, and the D2-like dopamine receptors, which include two isoforms of the D2 receptor (termed D2 s and D2 L ), the D3 and D4 receptors, and their variants (1). Dopamine receptors are important targets for pharmaceuticals used in the treatment of disorders such as Parkinson's disease, drug abuse, and schizophrenia. In particular, dopamine agonists with selective action on D2 receptors have been used as drugs of choice in the clinical management of PRL-secreting adenomas (2), with the normalization of PRL levels and shrinkage of tumors after long term daily doses of D2 receptor agonists. Hence, the druginduced regulation of dopamine receptors is of clinical importance. Although dopaminergic stimulation of a phosphotyrosine phosphatase (3) and inhibition of protein kinase C epsilon (4) have been implicated at least in part to account for the antiproliferative actions of dopamine, the molecular mechanisms involved in the long term maintenance of D2 receptor/cellular sensitivity to agonist are poorly understood. A common property of receptor-mediated hormonal signaling is the ability to undergo negative regulation (desensitization) to prevent stimulation overload of the signalresponse system. The D1 receptor, prototypical of other G protein-coupled receptors, is subject to multiple (temporally and biochemically distinct) levels of regulation after agonist exposure. In the short term, this involves rapid functional uncoupling of the D1 receptor from G protein (5-7) involving receptor phosphorylation and palmitoylation (5). In the intermediate term, this involves agonist-mediated receptor internalization (8), and in the longer term, it involves agonistinduced receptor down-regulation (5-7). In contrast, the regulation of the D2 L receptor, prototypical of D2-like receptors, does not appear to conform to this model.
D
OPAMINE receptors have been categorized on the basis of differences in pharmacological and biochemical characteristics and structure into the D1-like receptors, which include D1 and D5 receptors, and the D2-like dopamine receptors, which include two isoforms of the D2 receptor (termed D2 s and D2 L ), the D3 and D4 receptors, and their variants (1) . Dopamine receptors are important targets for pharmaceuticals used in the treatment of disorders such as Parkinson's disease, drug abuse, and schizophrenia. In particular, dopamine agonists with selective action on D2 receptors have been used as drugs of choice in the clinical management of PRL-secreting adenomas (2) , with the normalization of PRL levels and shrinkage of tumors after long term daily doses of D2 receptor agonists. Hence, the druginduced regulation of dopamine receptors is of clinical importance. Although dopaminergic stimulation of a phosphotyrosine phosphatase (3) and inhibition of protein kinase C epsilon (4) have been implicated at least in part to account for the antiproliferative actions of dopamine, the molecular mechanisms involved in the long term maintenance of D2 receptor/cellular sensitivity to agonist are poorly understood. A common property of receptor-mediated hormonal signaling is the ability to undergo negative regulation (desensitization) to prevent stimulation overload of the signalresponse system. The D1 receptor, prototypical of other G protein-coupled receptors, is subject to multiple (temporally and biochemically distinct) levels of regulation after agonist exposure. In the short term, this involves rapid functional uncoupling of the D1 receptor from G protein (5-7) involving receptor phosphorylation and palmitoylation (5) . In the intermediate term, this involves agonist-mediated receptor internalization (8) , and in the longer term, it involves agonistinduced receptor down-regulation (5) (6) (7) . In contrast, the regulation of the D2 L receptor, prototypical of D2-like receptors, does not appear to conform to this model.
Previous studies have shown that desensitization of the D2 L receptor-inhibited adenylyl cyclase system is slow to occur and results only after very prolonged agonist exposure for 24 h (9 -11). Yet, other studies have reported the absence of desensitization (12, 13) . Similarly, the effects of agonist on D2 L receptor density are controversial. Agonist exposure has been shown to not affect receptor density (9) , sequester receptors (14) , or up-regulate receptors on cultured cells (10 -13) . A clear explanation has been lacking, and it is unlikely to be attributed to differences in receptor expression level, because most of these studies used stably transfected or endogenously D2 receptor-expressing cells generating about 1 pmol receptor/mg protein (10 -14) . Agonist-induced up-regulation of D2 L receptors was also observed in cells expressing approximately 50 fmol of the receptor (12) . The likely explanation may be that these studies reported on different aspects of the biology of the D2 L receptor.
The recombinant baculovirus/Sf9 insect cell system has been shown to be highly suitable for the study of the structure and function of a wide range of heterologous genes. We have shown that Sf9 cells can express D2 L receptors to a specific activity of 1-2 pmol receptor/mg protein, and that expressed D2 L receptors are pharmacologically similar to their neuronal counterparts (15) . Further, we showed that D2 L receptors are appropriately posttranslationally modified in this cell line (15) , and others have shown that D2 L receptors expressed in the Sf9 cells are coupled to endogenous G proteins and mediate inhibition of adenylyl cyclase activity (16) . Hence, the baculovirus/Sf9 model system can be highly suitable for studies of a fundamental nature. The high target signal to low background is an advantage of the Sf9 cells that adds only to the confidence of the experimental results. Hence, the baculovirus/Sf9 model system was selected to clarify the mechanisms that may explain the differential regulation of the D2 L receptor after agonist exposure. The experiments described herein show that resistance of the D2 L receptor-coupled adenylyl cyclase to desensitization accompanies the up-regulation of surface receptors. This newly discovered replenishment mechanism is subject to at least two distinct mechanisms, involving, in the short term after agonist exposure, the redistribution of existing pools of receptors and, in the long term after agonist exposure, receptor synthesis.
Materials and Methods

Culture of D2 L receptor-expressing Sf9 cells
Fall armyworm ovary Sf9 (Spodoptera frugiperda) cells were purchased from American Type Culture Collection (Rockville, MD) and grown in supplemented Grace's insect medium with 10% FBS as previously described (15) . Sf9 cells adapted for permanent growth in serum-free Sf-900II medium were obtained from Life Technologies (Grand Island, NY). In all experiments, cells were maintained as a monolayer or suspension culture at 27 C, and at a density of 1-2 ϫ 10 6 cells/ml were infected with recombinant baculovirus encoding the human D2 L receptor (multiplicity of infection, ϳ5). All cells were harvested at the 48 h postinfection point. To minimize variations in recombinant baculovirus infection efficiencies among batches of cultures, the same recombinant virus stock was used in all experiments for this study.
Dopamine and cycloheximide treatments
D2 L receptor-expressing Sf9 cells were cultured in serum-free Grace's medium when examining the effects of dopamine. Dopamine treatments were performed for 3-4 h, similar to the t 1/2 reported for the upregulation of D2 L receptors expressed in HEK-293 cells (17) and CHO cells (10) , and were as long as 24 h, which was a common time point used in previous studies as well (10, 12, 13) . Dopamine was used at a 10-m final concentration in the presence of 0.01 mm ascorbic acid.
To confirm that agonist-induced up-regulation of D2 L receptors was not due to receptor synthesis, dopamine treatments were conducted in the presence of the protein synthesis inhibitor, cycloheximide. Cycloheximide was used at a final concentration of 10 g/ml. Cycloheximide at a concentration of 5 g/ml has been used to block protein synthesis in D2 L receptor-expressing CHO (10) and C 6 glioma (11) cells. Further, these studies used a Sf9 cell line adapted for permanent growth in serum-free Sf900II medium so as to eliminate serum catecholamine effects. Typically for all studies, cells were 90% viable or greater as assessed by exclusion of trypan blue stain. Incubations were terminated by pelleting cells at 100 ϫ g for 10 min and washing the cells extensively with ice-cold PBS.
Statistical significance between control and treatment conditions was determined by Student's paired t test.
Preparation of membrane fractions
Cells were pelleted by centrifugation at 100 ϫ g for 7 min, washed with PBS, and resuspended in 10 ml buffer A (5 mm Tris-HCl and 2 mm EDTA buffer, pH 7.4, containing the protease inhibitors: 10 g/ml benzamidine, 5 g/ml leupeptin, and 5 g/ml soybean trypsin inhibitor). The cell suspension was homogenized and centrifuged at 100 ϫ g for 7 min to pellet unbroken cells and nuclei. The S1 supernatant was collected and centrifuged at high speed (27,000 ϫ g for 20 min) washed once with buffer A, and centrifuged again at high speed to prepare the P2 membranes. P2 membranes were resuspended in buffer A and stored at Ϫ80 C or resuspended in buffer B (75 mm Tris-HCl, 12.5 mm MgCl 2 , and 2 mm EDTA, pH 7.4) and assayed immediately for adenylyl cyclase activity. Alternatively, the S1 supernatant was used to prepare a cell surface heavy plasma membrane fraction and an intracellular light vesicular membrane fraction that exhibits a lower density than that of the heavy plasma membrane (18, 19) . This was performed by layering the S1 supernatant on top of a 35% sucrose cushion, which was then subjected to centrifugation at 150,000 ϫ g for 90 min at 4 C. As reported by Lohse et al. (20) , the 0 -35% interface contains the light vesicular membrane fraction believed to contain sequestered receptors, whereas the heavy plasma membrane fraction containing surface receptors sediments at the bottom of the sucrose cushion. Heavy plasma and light intracellular membrane fractions were resuspended in buffer A and centrifuged at 200,000 ϫ g for 60 min. Pelleted membranes were resuspended in buffer A and stored at Ϫ70 C or resuspended in the appropriate buffers for immediate use in various assays. Membrane protein content was determined using a Bradford assay kit (Bio-Rad, Richmond, CA). 
Radioligand binding
Adenylyl cyclase assay
Freshly prepared P2 membranes from D2 L receptor-expressing cells were used for adenylyl cyclase determinations. The assay mix contained 0.02 ml membrane suspension (ϳ25 g protein), 0.012 mm ATP, 0.1 mm cAMP, 0.053 mm GTP, 2.7 mm phosphoenolpyruvate, 0.2 U pyruvate kinase, 1 U myokinase, and 0.13 Ci [ 32 P]ATP in a final volume of 0.05 ml. Enzyme activities were determined in triplicate assay tubes containing 10 Ϫ3 -10 Ϫ9 m dopamine with 10 m forskolin and incubated at 27 C for 20 min. Reactions were stopped by the addition of 1 ml of an ice-cold solution containing 0.4 mm ATP, 0.3 mm cAMP, and [
3 H]cAMP (25,000 cpm). cAMP was isolated by sequential column chromatography using Dowex cation exchange resin and aluminum oxide. Data were analyzed by computer-fitted nonlinear least squares regression (GraphPad InPlot version 4.03).
In situ immunofluorescence labeling
Cells expressing the receptor subtype of interest cultured in suspension (1.5 ϫ 10 6 /ml) were aliquoted into Eppendorf tubes for indirect immunocytofluorescent staining. For the visualization of receptors, cells were fixed with freshly prepared 4% paraformaldehyde in PBS for 15 min, washed in PBS, pelleted, and permeabilized with methanol at Ϫ70 C for 3 min. Immunocytochemical staining was performed at room temperature. To reduce nonspecific staining, cells were incubated for 1 h in a blocking solution of 1% BSA and 5% goat serum. The cells were then incubated with 9E10 primary antibody for the c-myc of c-myc D1 receptor or with the AL-26 polyclonal antibody for the D2 L receptor (a gift from Dr. Mark R. Brann, University of Vermont, Burlington, VT) followed by incubation with a fluorescein isothiocyanate-conjugated secondary antibody each for 1 h. Cells were washed with PBS for 15 min and pelleted. This was repeated twice before the cells were resuspended in the mounting medium Mowiol-88 (Hoechst, Montreal, Canada) to which 1,4-diazabicyclo[2.2.2]octane (Sigma Chemical Co., St. Louis, MO) had been added to reduce photobleaching. The visualization of whole cells by confocal microscopy and the protocol used for the classification of cell staining patterns have been reported in detail previously (8) .
SDS-PAGE and immunoblot analysis
Tissues were solubilized in sample buffer consisting of 50 mm TrisHCl (pH 6.5), 10% SDS, 10% glycerol, 0.003% bromophenol blue, and 10% 2-mercaptoethanol and electrophoresed on precast 12% mini-Trisglycine gels (Novex, San Diego, CA) under reducing and denaturing conditions. Samples were electroblotted onto nitrocellulose membrane and incubated with a D2 receptor-specific rabbit (AL-26) polyclonal antibody as reported previously (15) . Primary antibody-bound receptor was detected with a goat antirabbit IgG alkaline phosphatase conjugate (Bio-Rad). Blots were developed with 5-bromo-4-chloro-3-indoyl-phosphate/4-nitro blue tetrazolium chloride substrate (Bio-Rad) according to the manufacturer's instructions. Figure 1A shows the saturation isotherms for were observed in these dopamine-treated tissues, indicating that increased receptor density was not due to an increased affinity of the receptor for ligand. Sf9 cells infected with wild-type baculovirus did not show any specific [ 3 H]spiperone binding (data not shown). These data indicated that the D2 L receptor system responds to sustained agonist exposure at least in part by increasing receptor density on the surface of cells. Figure 1B shows dopamine competition of specific [ 3 H]spiperone binding to P2 membranes prepared from D2 L receptor-expressing cells treated with vehicle or dopamine for up to 3 h. Surprisingly, no significant differences were observed for dopamine-detected high and low affinity receptor states between vehicle-treated and dopamine-treated tissues. K i values and proportions for dopamine-detected high and low affinity states in vehicle-treated tissues were 32 Ϯ 4 nm (23%) and 31 Ϯ 4 m (77%) (n ϭ 4). K i values and proportions for dopamine-detected high and low affinity states for tissues treated with dopamine for 30 min were 30 Ϯ 7 nm (27%) and 41 Ϯ 10 m (73%) (n ϭ 3), and those for 3 h were 26 Ϯ 12 nm (24%) and 24 Ϯ 5 m (76%) (n ϭ 3). These data indicated that in comparison to dopamine D1 receptors, agonist-induced uncoupling of D2 L receptors from G proteins is slow to occur.
Results
Effects of agonist exposure on the pharmacological properties of the D2 L receptor system
Expressed D2 L receptors mediated dopamine inhibition (21.3 Ϯ 1.9%; n ϭ 4) of forskolin-stimulated adenylyl cyclase activity with an IC 50 of 22 Ϯ 6 nm (n ϭ 4; Fig. 1C ). After exposure of D2 L receptor-expressing cells to dopamine for 30 min, the efficacy and potency of receptors to mediate dopamine inhibition of forskolin-stimulated adenylyl cyclase activity was essentially unchanged (IC 50 of 31 Ϯ 11 nm; n ϭ 3; Fig. 1C ). However, longer periods of dopamine exposure (3 h) resulted in a marked loss of potency (IC 50 of 3.0 Ϯ 0.5 m; n ϭ 3) with little alteration in the efficacy of receptors to inhibit adenylyl cyclase activity (Fig. 1C) .
Agonist-mediated translocation of D2 L receptors from a light membrane fraction to a heavy membrane fraction
As several studies have reported no association between D2 receptor up-regulation and messenger RNA (mRNA) levels (11-13), we tested the hypothesis that the agonistpromoted up-regulation of receptors involved the redistribution of existing pools of receptors. The number of receptors present in the heavy cell surface plasma membrane and in the light intracellular vesicular membrane fraction were assessed directly by subcellular fractionation and radioligand binding experiments. Agonist exposure of D2 L receptor-expressing cells resulted in a slowly evolving translocation of D2 L receptors from the light membrane fraction to the heavy plasma membrane fraction (Fig. 2) . Receptor translocation was defined as an increase in the number of receptors in the cell surface heavy plasma membrane accompanied by a proportional decrease in the number of receptors in the light vesicular membrane. This D2 L receptor response to agonist stimulation began to plateau (18 Ϯ 4%; n ϭ 3; P Ͻ 0.05) after 1 h and appeared to be near maximal (28 Ϯ 6%; n ϭ 3; P Ͻ 0.05) after 6 h. Total receptor densities in vehicle-and dopamine-treated cells over this time period were not different. Total cellular receptor was defined as the total receptor density present in the heavy plasma membrane fraction added to the receptor density in the light intracellular vesicular membrane fraction. These data provide the scientific basis to suggest that the agonist-induced up-regulation of receptors on the cell surface was attributed to the redistribution of existing intracellular receptor pools.
Agonist mediated redistribution of dopamine receptors in whole cells
D2 receptor-specific antibodies enabled us to examine, via another independent measurement, the cellular distribution of the receptor by immunocytochemical staining (Fig. 3) . Receptor labeling was visualized by confocal immunofluorescent microscopy, which optically sections a cell such that D2 RECEPTOR DESENSITIZATION AND RECEPTOR UP-REGULATIONeach section or slice could be viewed individually. Cells were permeablized so that both cell surface and internally located receptors could be detected; hence, the technique provides a valuable spatial description of the effects of agonist on the cellular distribution of the receptor. All comparative analysis was performed under identical illuminating and viewing conditions.
At steady state, D2 L receptors exhibit a patchy distribution on the cell surface, with most of the receptors in intracellular compartments (Fig. 3A) . Dopamine exposure (10 m dopamine for 4 h) mediated a redistribution of internally located receptors to the cell surface, as evidenced by the loss of label in the cytoplasm and an accompanying increase in the ring of fluorescence on the cell surface (compare A to B).
For comparison, the effects of agonist exposure on the cellular distribution of a c-myc epitope-tagged D1 receptor was assessed in the identical Sf9 cell line. Figure 3D shows that at steady state, c-myc D1 receptors are diffuse over the cell surface, appearing as a bright and continuous ring. Internally located receptors appear as clusters of label, which may represent localization to intracellular compartments or vesicles. In cells pretreated with 10 m dopamine for 1 h, cell surface receptor labeling changed from a bright continuous ring to a broken and less intense ring with increased intracellular pockets of label (compare D to E). These data suggest that dopamine mediated a redistribution and reduction of the number of surface D1 receptors, data we have described in detail previously (8) . Control cells, expressing no receptors, are barely visible, reflecting the absence of specific immunocytochemical labeling (Fig. 3, C and F) . The results of these experiments demonstrated for the first time distinct regulation of D1 and D2 L receptors when expressed in the same foster cell line. Moreover, the differences in receptor redistribution observed for D1 and D2 L receptors after agonist treatment in the identical Sf9 cell line provide evidence that these are receptor subtype-specific responses and not an artifact of the cell line.
Agonist-promoted up-regulation of surface D2 L receptor monomers and dimers
Immunoblot analysis of the P2 membrane fraction prepared from D2 L receptor-expressing cells showed that D2 L receptors were composed of an approximately 44-kDa species representing a receptor monomer and, at approximately twice the molecular mass, an approximately 98-kDa form, representing a receptor dimer (Fig. 4, lane 1) . The biophysicochemical properties of the D2 L receptor dimer have been recently reported (21) . Immunoblot of a P2 membrane fraction prepared from D2 L receptor-expressing cells treated with dopamine showed an increase in both receptor monomer and dimer (Fig. 4, compare lanes 1 and 2) , consistent with radioligand binding data. Taken together, these results raise the speculation of a functional role for D2 dimers in the response to agonist.
Effects of cycloheximide on agonist-induced up-regulation of the D2 L receptor
To confirm that the agonist-induced up-regulation of surface D2 L receptors was not attributed to receptor synthesis, dopamine treatments were conducted in the presence of the protein synthesis inhibitor cycloheximide. Further, these studies used Sf9 cells that had been permanently adapted for growth in serum-free medium so as to eliminate potential effects of contaminating catecholamines in serum. D2 L receptor density was estimated in these experiments by [ 3 H]nemonapride binding, as we have recently shown that this benzamide antagonist binds both monomeric and dimeric forms of the D2 L receptor (21) . Hence, the nemonapride ligand would provide a good estimate of the up-regulation of D2 L receptor monomers and dimers after agonist exposure, as revealed by immunoblot analysis (Fig. 4) . D2 L receptors were expressed to 706 Ϯ 143 fmol receptor/mg protein (n ϭ 3) in serum-free adapted Sf9 cells, which was significantly reduced to 460 Ϯ 37 fmol receptor/mg protein (n ϭ 3) after treatment with cycloheximide for 4 h (P Ͻ 0.05). Figure 5 shows that treatment of D2 L receptorexpressing cells with cycloheximide did not block the dopamine-induced up-regulation of D2 L receptor density after 4 h of agonist exposure. These findings support the radioligand binding and whole cell immunocytochemical studies showing that the agonist-promoted up-regulation of surface D2 L receptors involved existing pools of receptors.
Several studies have reported an agonist-promoted increase in D2 L receptor density after prolonged (24 h) agonist exposure. Our studies showed that treatment of D2 L receptor-expressing Sf9 cells with dopamine for 24 h led to a small, but insignificant, increase (P Ͼ 0.05) in receptor density, rising from 565 Ϯ 52 (n ϭ 3) to 700 Ϯ 74 (n ϭ 3) fmol receptor/mg protein. However, when these studies were repeated in the presence of cycloheximide, dopamine exposure for 24 h led to a marginally significant decrease (P ϭ 0.06) in receptor density (Fig. 5) . Taken together, these studies suggest the need for de novo receptor synthesis in the maintenance of cell surface receptor density after prolonged 24-h dopamine treatment.
Discussion
D2 receptors are important targets of drugs used for the treatment of pituitary adenomas, in particular macroprolactinomas (2). In the latter case, tumor shrinkage occurs during the early months of treatment, and drug withdrawal almost always results in a return of hyperprolactinemia regardless of the duration of treatment. However, continued D2 agonist use maintains control of PRL secretion and tumor growth. To date, a clear mechanism to explain the long term efficacy of dopamine agonists has been lacking. To better understand the mechanisms underlying the maintenance of the D2 receptor/cellular sensitivity to dopamine agonists, we studied D2 L receptor function in Sf9 insect cells, which we and others have proven to be highly suitable for G-linked receptor studies of a fundamental nature (21, 22) .
Agonist treatment of D2 L receptor-expressing cells for 3 h resulted in no detectable change in ligand-binding properties, but a loss of potency (but not efficacy) of the D2 L receptor to inhibit adenylyl cyclase activity was observed, indicating that sustained agonist exposure initiates the desensitization process. These findings are in good agreement with the reported resistance (and/or slow onset) of the D2 L receptorcoupled adenylyl cyclase to negative regulation by agonist in other mammalian cell systems (9 -13). However, no clear mechanism has yet been linked to this receptor/cellular adaptation. It has been suggested that agonist binding to vitamin D receptors may render the receptor conformationally more stable (23) , a mechanism that may account for the differential response of the D2 L receptor-coupled adenylyl cyclase system to sustained agonist exposure. Our data show that the resistance of the D2 L receptor to desensitization occurred with an agonist-promoted up-regulation of surface receptors that comprised receptor monomers and dimers. D2 L dimers may represent a newly discovered functional intermediate in the response to agonist exposure; this work is underway. In fact, recent evidence showed possible biological activity for the ␤ 2 -adrenergic receptor dimer (22) . Our subcellular fractionation and radioligand binding and whole cell confocal microscopy studies suggested that the agonistpromoted receptor up-regulation involved existing pools of receptors. Indeed, we showed that the agonist-promoted up-regulation of surface D2 L receptors was not blocked by the protein synthesis inhibitor cycloheximide, which supports this conclusion. Further, the GnRH receptor has been reported to up-regulate when exposed to GnRH and does not appear to involve regulation of the synthesis or stability of receptor mRNA (24) . It has been postulated that intracellular receptors could serve as reserve pools of receptors that may be induced by agonist to translocate to the cell surface or into functional microdomains (25, 26) . We provide evidence to support this claim. Interestingly, agonist treatment has been shown to result in the up-regulation of D2-like dopamine D3 receptors on cultured C 6 cells as well (27) , suggesting that this may constitute a more general adaptive response in this receptor subfamily.
In contrast to the majority of D2 L receptor regulation studies, a single report has recently shown the agonist-promoted sequestration of the D2 L receptor based on the loss of hydrophilic [ 3 H]sulpiride binding, with total hydrophobic [ 3 H]spiperone binding remaining unchanged (14) . Differences in receptor expression among the studies probably does not account for the conflicting results, as most of the studies used stably transfected or endogenously D2 L receptor-expressing cells or, as shown herein, D2 L receptor expressing Sf9 cells generating approximately 1 pmol receptor/mg protein (10 -14) . It could be explained that agonist exposure triggers a conformational change in surface D2 L receptors, possibly rendering receptors refractory or inaccessible to hydrophilic ligands, as suggested previously for a model of ␤ 2 -adrenergic receptor sequestration (28) . Indeed, it was recently reported that agonist treatment of D2 L receptor-expressing HEK-293 cells led to a decreased proportion of surface receptors in the high affinity, agonist-preferring state as assessed by [
125 I]7-hydroxy-2-[N-n-propyl-N-(3Ј-iodo-2Ј-propenyl)-amino]tetralin binding (17 (10 -14) may have simply monitored different aspects of D2 L receptor biology. That total hydrophobic spiperone binding remained unchanged in the D2 L receptor sequestration study is consistent with our data, which support the conclusion that the up-regulation of surface D2 L receptors after shorter term agonist exposure (3-4 h) involved existing pools of receptors.
Different mechanisms appear to be involved in regulating cellular D2 L receptor density after prolonged (24-h) dopamine treatment. We observed no significant increase in D2 L receptor density after 24-h agonist exposure. When these studies were conducted in the presence of cycloheximide, dopamine exposure led to a marginal decrease in surface D2 L receptor density. This suggests that prolonged dopamine exposure may lead to the down-regulation of receptors and that de novo protein synthesis plays an important role in the agonist-promoted up-regulation of D2 L receptor density under these conditions. In agreement with this idea, sustained agonist exposure has been associated with an increase in the steady state level of D2 L mRNA in D2 L receptor-expressing CHO cells (10) . Agonist-induced up-regulation of 5-HT 2 receptors on cultured cerebellar neurons and of ␤ 2 -adrenergic and ␤ 3 -adrenergic receptors in cultured cells (29 -31) has also been attributed to alterations in transcriptional or translational activity (biosynthesis rate and/or altered stability and levels of receptor mRNA). Taken together, these results suggest that surface D2 L receptor density is regulated by protein synthesis over the long term (24 h) after agonist exposure.
Several observations provide interesting speculations about possible mechanisms underlying D2 L receptor trafficking. First, G ␣i3 proteins, to which D2 receptors have been reported to couple (32) , have been implicated in the activation of noncoated vesicle-mediated exocytosis (33) . Second, G ␤␥ dimers have been shown to regulate not only receptor kinase-mediated phosphorylation and desensitization of receptors, but also intracellular vesicular trafficking (25, 34) . These findings suggest that G proteins may play a role in D2 receptor trafficking. Interestingly, treatment of D2 L /CHO cells and D2L/HEK 293 cells with pertussis toxin blocked dopamine-induced receptor up-regulation (10, 16) , although a single study showed no effect (11) .
D2 receptor-mediated mechanisms are important for autoreceptor function in dopamine neurons and in tonic inhibitory functions, such as the inhibition of PRL or ␣MSH secretion. The sensitivity of D2 receptor agonists during long term control of PRL-secreting adenomas is exquisite, but the mechanisms remain unknown. Hence, the relative insensitivity of the D2 receptor system to desensitization by agonist reported herein appears to be functionally important. It should also be noted that D2 receptor up-regulation and behavioral supersensitivity to D2 agonist have been observed in animals treated with indirect dopamine agonists (35) (36) (37) (38) , for which we now provide a mechanistic basis. In turn, this observation substantiates the high likelihood that our results are physiologically relevant. We propose that the newly discovered recruitment of existing intracellular D2 L receptors to the cell surface, resulting in the up-regulation of D2 L receptor monomers and dimers, and the longer term de novo receptor synthesis after agonist exposure contribute to the sustained pattern of agonist-mediated activation of D2 L receptor-linked intracellular events.
